Insider Transactions in Q1 2024 at Kala Pharmaceuticals, Inc. (KALA)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 04
2024
|
Romulus K Brazzell |
SELL
Open market or private sale
|
Direct |
1,617
-1.74%
|
$9,702
$6.74 P/Share
|
|
Jan 04
2024
|
Romulus K Brazzell |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+6.53%
|
-
|
|
Jan 04
2024
|
Darius Kharabi CHIEF BUSINESS OFFICER |
SELL
Open market or private sale
|
Direct |
1,385
-2.08%
|
$8,310
$6.73 P/Share
|
|
Jan 04
2024
|
Darius Kharabi CHIEF BUSINESS OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
4,600
+6.47%
|
-
|
|
Jan 04
2024
|
Eric Trachtenberg |
SELL
Open market or private sale
|
Direct |
1,227
-1.77%
|
$7,362
$6.74 P/Share
|
|
Jan 04
2024
|
Eric Trachtenberg |
BUY
Grant, award, or other acquisition
|
Direct |
4,600
+6.23%
|
-
|
|
Jan 04
2024
|
Todd Bazemore |
SELL
Open market or private sale
|
Direct |
1,405
-1.54%
|
$8,430
$6.74 P/Share
|
|
Jan 04
2024
|
Todd Bazemore |
BUY
Grant, award, or other acquisition
|
Direct |
6,500
+6.65%
|
-
|
|
Jan 04
2024
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
1,227
-1.82%
|
$7,362
$6.74 P/Share
|
|
Jan 04
2024
|
Mary Reumuth CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
4,600
+6.39%
|
-
|
|
Jan 04
2024
|
Mark T Iwicki CHIEF EXECUTIVE OFFICER |
SELL
Open market or private sale
|
Direct |
4,539
-1.56%
|
$27,234
$6.73 P/Share
|
|
Jan 04
2024
|
Mark T Iwicki CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
14,300
+4.69%
|
-
|